Related Experiment Video
Updated: Mar 15, 2026
Author Spotlight: Integrating High-Resolution Intravital Imaging and MRI to Enhance Stereotactic Body Radiation Therapy Planning
Published on: April 12, 2024
Imaging approaches to optimize molecular therapies
Ralph Weissleder1, Markus C Schwaiger2, Sanjiv Sam Gambhir3
1Massachusetts General Hospital, Boston, MA 02114, USA. rweissleder@mgh.harvard.edu.
Abstract:
Imaging, including its use for innovative tissue sampling, is slowly being recognized as playing a pivotal role in drug development, clinical trial design, and more effective delivery and monitoring of molecular therapies. The challenge is that, while a considerable number of new imaging technologies and new targeted tracers have been developed for cancer imaging in recent years, the technologies are neither evenly distributed nor evenly implemented. Furthermore, many imaging innovations are not validated and are not ready for widespread use in drug development or in clinical trial designs. Inconsistent and often erroneous use of terminology related to quantitative imaging biomarkers has also played a role in slowing their development and implementation. We examine opportunities for, and challenges of, the use of imaging biomarkers to facilitate development of molecular therapies and to accelerate progress in clinical trial design. In the future, in vivo molecular imaging, image-guided tissue sampling for mutational analyses ("high-content biopsies"), and noninvasive in vitro tests ("liquid biopsies") will likely be used in various combinations to provide the best possible monitoring and individualized treatment plans for cancer patients.
Insights
Molecular imaging advances drug development and clinical trials. Challenges in technology implementation and terminology hinder progress, but future combinations of imaging and biopsies promise personalized cancer care.
Area of Science:
- Biomedical Imaging
- Molecular Therapy Development
- Oncology
Background:
- Molecular imaging is crucial for drug development, clinical trials, and therapy monitoring.
- Numerous new imaging technologies and targeted tracers exist for cancer, but implementation is uneven.
- Many imaging innovations lack validation for widespread use in drug development or clinical trials.
Purpose of the Study:
- To examine opportunities and challenges of using imaging biomarkers for molecular therapy development.
- To explore how imaging biomarkers can accelerate clinical trial design.
- To discuss the future integration of advanced imaging techniques for personalized cancer treatment.
Main Methods:
- Review of current imaging technologies and targeted tracers in cancer research.
- Analysis of challenges in the implementation and validation of imaging innovations.
- Examination of terminology issues related to quantitative imaging biomarkers.
Main Results:
- Despite technological advancements, uneven distribution and implementation of imaging technologies persist.
- Lack of validation and inconsistent terminology impede the development and use of imaging biomarkers.
- Opportunities exist to leverage imaging for improved molecular therapy development and clinical trial efficiency.
Conclusions:
- Integrating in vivo molecular imaging with image-guided biopsies and liquid biopsies will enhance cancer patient monitoring.
- Personalized treatment plans can be optimized through a combination of advanced imaging and molecular analyses.
- Overcoming current challenges is key to realizing the full potential of molecular imaging in oncology.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:45Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
Published on: October 25, 2024
